Skip to main content
All lobbying filings

BIOMARIN PHARMACEUTICAL INC.

Lobbying for BIOMARIN PHARMACEUTICAL INC.

 Filing 3rd Quarter - Report
Reporting period
3rd Quarter 2025
July 1 - Sep 30 · Posted Oct 20, 2025
Expenses
$270,000.00
What this organization spent lobbying with its own staff. Reported using A: the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 3
  • Commerce, Dept of (DOC)
  • HOUSE OF REPRESENTATIVES
  • SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

 Bills named in this filing 5
  • HR 1262
    Mikaela Naylon Give Kids a Chance Act
  • S 932
    Give Kids a Chance Act of 2025
  • HR 1509
    Accelerating Kids’ Access to Care Act of 2025
  • S 752
    Accelerating Kids’ Access to Care Act
  • S 1637
    MVP Act
 Lobbying activity 5
Budget/Appropriations

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG EXCLUSIVITY

Health Issues

H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM

Medicare/Medicaid

H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING

Tariff (miscellaneous tariff bills)

GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS

Taxation/Internal Revenue Code

GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem